AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation

Alexandre V. Ivachtchenko, Ilya Okun, Vladimir Aladinskiy, Yan Ivanenkov, Angela Koryakova, Ruben Karapetyan, Oleg Mitkin, Ramiz Salimov, Andrey Ivashchenko, Ilya Bezprozvanny

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Discovery of 5-HT6 receptor subtype and its exclusive localization within the central nervous system led to extensive investigations of its role in Alzheimer's disease, schizophrenia, and obesity. In the present study, we present preclinical evaluation of a novel highly-potent and highly-selective 5-HT6R antagonist, AVN-492. The affinity of AVN-492 to bind to 5-HT6R (Ki = 91 pM) was more than three orders of magnitude higher than that to bind to the only other target, 5-HT2BR, (Ki = 170 nM). Thus, the compound displayed great 5-HT6R selectivity against all other serotonin receptor subtypes, and is extremely specific against any other receptors such as adrenergic, GABAergic, dopaminergic, histaminergic, etc. AVN-492 demonstrates good in vitro and in vivo ADME profile with high oral bioavailability and good brain permeability in rodents. In behavioral tests, AVN-492 shows anxiolytic effect in elevated plus-maze model, prevents an apomorphine-induced disruption of startle pre-pulse inhibition (the PPI model) and reverses a scopolamine- and MK-801-induced memory deficit in passive avoidance model. No anti-obesity effect of AVN-492 was found in a murine model. The data presented here strongly indicate that due to its high oral bioavailability, extremely high selectivity, and potency to block the 5-HT6 receptor, AVN-492 is a very promising tool for evaluating the role the 5-HT6 receptor might play in cognitive and neurodegenerative impairments. AVN-492 is an excellent drug candidate to be tested for treatment of such diseases, and is currently being tested in Phase I trials.

Original languageEnglish (US)
Pages (from-to)1043-1063
Number of pages21
JournalJournal of Alzheimer's Disease
Volume58
Issue number4
DOIs
StatePublished - 2017

Fingerprint

Biological Availability
Obesity
Scopolamine Hydrobromide
Dizocilpine Maleate
Apomorphine
Serotonin Receptors
Anti-Anxiety Agents
Memory Disorders
Adrenergic Agents
Rodentia
Permeability
Schizophrenia
Alzheimer Disease
Central Nervous System
Brain
Pharmaceutical Preparations
serotonin 6 receptor
In Vitro Techniques
Inhibition (Psychology)
Cognitive Dysfunction

Keywords

  • 5-HT receptor
  • Alzheimer's disease
  • antagonists
  • anti-anxiety agents
  • central nervous system agents
  • memory enhancement
  • obesity
  • schizophrenia

ASJC Scopus subject areas

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Ivachtchenko, A. V., Okun, I., Aladinskiy, V., Ivanenkov, Y., Koryakova, A., Karapetyan, R., ... Bezprozvanny, I. (2017). AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation. Journal of Alzheimer's Disease, 58(4), 1043-1063. https://doi.org/10.3233/JAD-161262

AVN-492, A Novel Highly Selective 5-HT6R Antagonist : Preclinical Evaluation. / Ivachtchenko, Alexandre V.; Okun, Ilya; Aladinskiy, Vladimir; Ivanenkov, Yan; Koryakova, Angela; Karapetyan, Ruben; Mitkin, Oleg; Salimov, Ramiz; Ivashchenko, Andrey; Bezprozvanny, Ilya.

In: Journal of Alzheimer's Disease, Vol. 58, No. 4, 2017, p. 1043-1063.

Research output: Contribution to journalArticle

Ivachtchenko, AV, Okun, I, Aladinskiy, V, Ivanenkov, Y, Koryakova, A, Karapetyan, R, Mitkin, O, Salimov, R, Ivashchenko, A & Bezprozvanny, I 2017, 'AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation', Journal of Alzheimer's Disease, vol. 58, no. 4, pp. 1043-1063. https://doi.org/10.3233/JAD-161262
Ivachtchenko AV, Okun I, Aladinskiy V, Ivanenkov Y, Koryakova A, Karapetyan R et al. AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation. Journal of Alzheimer's Disease. 2017;58(4):1043-1063. https://doi.org/10.3233/JAD-161262
Ivachtchenko, Alexandre V. ; Okun, Ilya ; Aladinskiy, Vladimir ; Ivanenkov, Yan ; Koryakova, Angela ; Karapetyan, Ruben ; Mitkin, Oleg ; Salimov, Ramiz ; Ivashchenko, Andrey ; Bezprozvanny, Ilya. / AVN-492, A Novel Highly Selective 5-HT6R Antagonist : Preclinical Evaluation. In: Journal of Alzheimer's Disease. 2017 ; Vol. 58, No. 4. pp. 1043-1063.
@article{57cecce8548b48b7807b597b0d060212,
title = "AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation",
abstract = "Discovery of 5-HT6 receptor subtype and its exclusive localization within the central nervous system led to extensive investigations of its role in Alzheimer's disease, schizophrenia, and obesity. In the present study, we present preclinical evaluation of a novel highly-potent and highly-selective 5-HT6R antagonist, AVN-492. The affinity of AVN-492 to bind to 5-HT6R (Ki = 91 pM) was more than three orders of magnitude higher than that to bind to the only other target, 5-HT2BR, (Ki = 170 nM). Thus, the compound displayed great 5-HT6R selectivity against all other serotonin receptor subtypes, and is extremely specific against any other receptors such as adrenergic, GABAergic, dopaminergic, histaminergic, etc. AVN-492 demonstrates good in vitro and in vivo ADME profile with high oral bioavailability and good brain permeability in rodents. In behavioral tests, AVN-492 shows anxiolytic effect in elevated plus-maze model, prevents an apomorphine-induced disruption of startle pre-pulse inhibition (the PPI model) and reverses a scopolamine- and MK-801-induced memory deficit in passive avoidance model. No anti-obesity effect of AVN-492 was found in a murine model. The data presented here strongly indicate that due to its high oral bioavailability, extremely high selectivity, and potency to block the 5-HT6 receptor, AVN-492 is a very promising tool for evaluating the role the 5-HT6 receptor might play in cognitive and neurodegenerative impairments. AVN-492 is an excellent drug candidate to be tested for treatment of such diseases, and is currently being tested in Phase I trials.",
keywords = "5-HT receptor, Alzheimer's disease, antagonists, anti-anxiety agents, central nervous system agents, memory enhancement, obesity, schizophrenia",
author = "Ivachtchenko, {Alexandre V.} and Ilya Okun and Vladimir Aladinskiy and Yan Ivanenkov and Angela Koryakova and Ruben Karapetyan and Oleg Mitkin and Ramiz Salimov and Andrey Ivashchenko and Ilya Bezprozvanny",
year = "2017",
doi = "10.3233/JAD-161262",
language = "English (US)",
volume = "58",
pages = "1043--1063",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - AVN-492, A Novel Highly Selective 5-HT6R Antagonist

T2 - Preclinical Evaluation

AU - Ivachtchenko, Alexandre V.

AU - Okun, Ilya

AU - Aladinskiy, Vladimir

AU - Ivanenkov, Yan

AU - Koryakova, Angela

AU - Karapetyan, Ruben

AU - Mitkin, Oleg

AU - Salimov, Ramiz

AU - Ivashchenko, Andrey

AU - Bezprozvanny, Ilya

PY - 2017

Y1 - 2017

N2 - Discovery of 5-HT6 receptor subtype and its exclusive localization within the central nervous system led to extensive investigations of its role in Alzheimer's disease, schizophrenia, and obesity. In the present study, we present preclinical evaluation of a novel highly-potent and highly-selective 5-HT6R antagonist, AVN-492. The affinity of AVN-492 to bind to 5-HT6R (Ki = 91 pM) was more than three orders of magnitude higher than that to bind to the only other target, 5-HT2BR, (Ki = 170 nM). Thus, the compound displayed great 5-HT6R selectivity against all other serotonin receptor subtypes, and is extremely specific against any other receptors such as adrenergic, GABAergic, dopaminergic, histaminergic, etc. AVN-492 demonstrates good in vitro and in vivo ADME profile with high oral bioavailability and good brain permeability in rodents. In behavioral tests, AVN-492 shows anxiolytic effect in elevated plus-maze model, prevents an apomorphine-induced disruption of startle pre-pulse inhibition (the PPI model) and reverses a scopolamine- and MK-801-induced memory deficit in passive avoidance model. No anti-obesity effect of AVN-492 was found in a murine model. The data presented here strongly indicate that due to its high oral bioavailability, extremely high selectivity, and potency to block the 5-HT6 receptor, AVN-492 is a very promising tool for evaluating the role the 5-HT6 receptor might play in cognitive and neurodegenerative impairments. AVN-492 is an excellent drug candidate to be tested for treatment of such diseases, and is currently being tested in Phase I trials.

AB - Discovery of 5-HT6 receptor subtype and its exclusive localization within the central nervous system led to extensive investigations of its role in Alzheimer's disease, schizophrenia, and obesity. In the present study, we present preclinical evaluation of a novel highly-potent and highly-selective 5-HT6R antagonist, AVN-492. The affinity of AVN-492 to bind to 5-HT6R (Ki = 91 pM) was more than three orders of magnitude higher than that to bind to the only other target, 5-HT2BR, (Ki = 170 nM). Thus, the compound displayed great 5-HT6R selectivity against all other serotonin receptor subtypes, and is extremely specific against any other receptors such as adrenergic, GABAergic, dopaminergic, histaminergic, etc. AVN-492 demonstrates good in vitro and in vivo ADME profile with high oral bioavailability and good brain permeability in rodents. In behavioral tests, AVN-492 shows anxiolytic effect in elevated plus-maze model, prevents an apomorphine-induced disruption of startle pre-pulse inhibition (the PPI model) and reverses a scopolamine- and MK-801-induced memory deficit in passive avoidance model. No anti-obesity effect of AVN-492 was found in a murine model. The data presented here strongly indicate that due to its high oral bioavailability, extremely high selectivity, and potency to block the 5-HT6 receptor, AVN-492 is a very promising tool for evaluating the role the 5-HT6 receptor might play in cognitive and neurodegenerative impairments. AVN-492 is an excellent drug candidate to be tested for treatment of such diseases, and is currently being tested in Phase I trials.

KW - 5-HT receptor

KW - Alzheimer's disease

KW - antagonists

KW - anti-anxiety agents

KW - central nervous system agents

KW - memory enhancement

KW - obesity

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85021266412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021266412&partnerID=8YFLogxK

U2 - 10.3233/JAD-161262

DO - 10.3233/JAD-161262

M3 - Article

C2 - 28550249

AN - SCOPUS:85021266412

VL - 58

SP - 1043

EP - 1063

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -